Plexxikon

Michael Sterba

Vice President, Clinical Operations

Michael Sterba was named vice president of clinical operations in April 2021, having previously served as director and senior director of clinical operations since joining Plexxikon in 2017. He and his clinical operations colleagues are responsible for management of clinical trial vendors and sites, pharmacovigilance, biometrics, medical writing, and trial master files. A key priority for Michael and his team has been support of the NDA for Plexxikon's FDA-approved drug Turalio®. Prior to joining Plexxikon, Michael was Executive Director of Clinical Operations at Rigel Pharmaceuticals, Inc. At Rigel from 2001 to 2017, he initially supported project management and toxicology before focusing for 15 years on various aspects of clinical trial execution for 10 small molecule NCEs, including the FDA-approved drug Tavalisse®. He began his career at Sugen, Inc. from 1999 to 2001, where he contributed to preclinical evaluation of the FDA-approved drug Sutent®. Michael earned his BS in pharmacology at the University of California, Santa Barbara.

Plexxikon, Inc.
329 Oyster Point, South San Francisco, CA 94080 t 510.647.4000 f 510.548.8014 www.plexxikon.com